Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Not yet recruiting 4Unknown 3Recruiting 3Completed 2Active not recruiting 1

Sponsor Class

OTHER 3OTHER_GOV 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Breast Neoplasms 549Neoplasms 384Carcinoma, Non-Small-Cell Lung 319Colorectal Neoplasms 290Lung Neoplasms 239Prostatic Neoplasms 219Carcinoma, Hepatocellular 212Stomach Neoplasms 158Pancreatic Neoplasms 151Leukemia, Myeloid, Acute 139Multiple Myeloma 130Uterine Cervical Neoplasms 127Recurrence 116Rectal Neoplasms 112Ovarian Neoplasms 105Neoplasm Metastasis 104Squamous Cell Carcinoma of Head and Neck 97Head and Neck Neoplasms 89Esophageal Neoplasms 85Triple Negative Breast Neoplasms 84Glioblastoma 80Small Cell Lung Carcinoma 79Endometrial Neoplasms 79Colonic Neoplasms 78Brain Neoplasms 78Melanoma 69Precursor Cell Lymphoblastic Leukemia-Lymphoma 66Hematologic Neoplasms 64Glioma 62Motor Activity 60

Interventions

tislelizumab 1Oxaliplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × Immunotherapy × Clear all
NCT07191405 2025-09-24

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase NA Not yet recruiting
156 enrolled

Immunotherapy

NCT07155811 2025-09-04

T-ECHNICO

Centre Leon Berard

Phase NA Not yet recruiting
100 enrolled
Other solid neoplasm

Immunotherapy

NCT05909137 2025-07-14

Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer

Xinqiao Hospital of Chongqing

Not yet recruiting
60 enrolled
Thoracic

Immunotherapy

NCT05479240 2023-06-18

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

Fujian Cancer Hospital

Phase 2 Not yet recruiting
94 enrolled

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡